Kass J, Brümmer M, Gruner C, Rötzer RD, Fenske S, Hartmann J, Zott B, Lüthi A, Spahn S, Moser M, Isbrandt D, Ludwig A, Konnerth A, Wahl-Schott C, Biel M. 2019. „Abolishing cAMP sensitivity in HCN2 pacemaker [...] Ulrich, S., Haller, R., Martin, U., and Merkert, S. 2019.„Generation of a CFTR knock-in reporter cell line (MHHi006-A-1) from a human induced pluripotent stem cell line”. Stem Cell Res 40, 101542 https://doi [...] 2018;46(3):1198-1208. https://doi.org/10.1159/000489070 2017 Ruhe F, Olling A, Abromeit R, Rataj D, Grieschat M, Zeug A, Gerhard R, Alekov A. 2017. „Overexpression of the Endosomal Anion/Proton Exchanger ClC-5

C, Weigel RE, Wolf ME, Heissler HE, Saryyeva A, Krauss JK. Microelectrode recording and hemorrhage in functional neurosurgery: a comparative analysis in a consecutive series of 645 procedures. J Neurosurg [...] JNS23613 Koy A, Kühn AA, Schiller P, Huebl J, Schneider GH, Eckenweiler M, Rensing-Zimmermann C, Coenen VA, Krauss JK, Saryyeva A, Hartmann H, Lorenz D, Volkmann J, Matthies C, Schnitzler A, Vesper J, [...] Gharabaghi A, Weiss D, Bevot A, Marks W, Howser A, Monbaliu E, Mueller J, Prinz-Langenohl R, Visser-Vandewalle V, Timmermann L; STIM-CP investigators. Long-Term Follow-Up of Pediatric Patients with Dyskinetic

n G, Staudt M, Noels H, Klos A, Fischer J, Bernhagen J, Zernecke A, Liehn EA, Shagdarsuren E. Cardiac repair after myocardial infarction is controlled by a complement C5a receptor 1-driven signaling cascade [...] Jochim-Vukosavic A, Schwab F, Knegendorf L, Schlüter D, Bange FC, Ebadi E*, Baier C*. Epidemiology and infection control of vancomycin-resistant enterococci at a German university hospital: A three-year r [...] eLlife. 2024; 12:RP91157. Wißing MH, Meister TL, Nocke MK, Gömer A, Masovic M, Knegendorf L, Brüggemann Y, Bader V, Siddharta A, Bock CT, Ploss A, Kenney SP, Winklhofer KF, Behrendt P, Wedemeyer H, Steinmann

Roger, Y., Hoffmann, A. (2020): Regeneration of Damaged Tendon-Bone Junctions (Entheses): TAK1 as a Potential Node Factor. Int J Mol Sci;21:E5177. Lavrentieva, A.*, Hoffmann, A.*, Lee-Thedieck, C.* (2020) [...] Schwieger, J., Hamm, A., Gepp, M.M., Schulz, A., Hoffmann, A. , Lenarz, T., Scheper, V. (2020) : Alginate-encapsulated Brain Derived Neurotrophic Factor-overexpressing mesenchymal stem cells are a promising drug [...] Brehm, R., Hoffmann, A. , de Cassan, D., Menzel, H., Hoheisel, A.-L., Glasmacher, B., Willbold, E., Reifenrath, J., Ludwig, N., Zimmerer, R., Tavassol, F., Gellrich, N.-C., Kampmann, A. (2020) : Vascularization

BoNTs in E. coli aufgebaut. Dr. Rummel war bzw. ist u.a. Antragssteller und Projektleiter in den vom BMBF/BMFTR geförderten Projekten FuMiBoNT(Fk 031A212A; Abschlussbericht ), SensTox (Fk 13N13794; Abschl [...] Andreas Rummel E-Mail Literatur [1] Rummel, A., The long journey of botulinum neurotoxins into the synapse. Toxicon, 2015. 107 (Pt A): p. 9-24. [2] Rummel, A., Two Feet on the Membrane: Uptake of Clostridial [...] Opin Pharmacol, 2005. 5 (3): p. 274-9. [6] Kutschenko, A., et al., Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients. Clin Neurophysiol, 2019

context of your own research work. The final exam is conducted in form of a public defense. Short-time stays abroad in a lab of a cooperation partner are possible. At the beginning, orientation weeks help [...] the Hannover Biomedical Research School (HBRS) has been organizing a joint curriculum for all programs ( Curriculum 2025/26 ). As a general rule, students have to attend 300 hours of teaching during the [...] journals as part of a cumulative thesis are desired). So, the average length of PhD at the moment is 3.8 years. We have an intermediate exam after 18 months. Here, you select and discuss a state-of-the-art

Phys Med Rehab Kuror 2019; 29: 184-185 Kröz M, Mehl A, Didwiszus A, Gelin-Kröz B, Reif M, Berger B, ten Brink F, Zerm R, Girke M, Gutenbrunner C, Büssing A. Reliability and first validity of the inner cor [...] (ICPTh) in a sample of breast cancer patients. Complementary Therapies in Medicine 2019; 42: 355–360 Liebl ME, Beyer J, Deventer A, Glaesener JJ, Lange U, Lemhöfer C, Mau W, Pioch E, Reißhauer A, Schwarzkopf [...] (Peer-Reviewed) Andreeva E, Neumann M, Nöhre M, Brähler E, Hilbert A, de Zwaan M. Validation of the German Version of the Power of Food Scale in a General Population Sample. Obes Facts. 2019 Jul 2:1-11. doi:

Dezember 2021: Deffner T, Hierundar A, Knochel K, Münch U, Neitzke G, Nydahl P, Rogge A (2021) Intensivmedizin: Besuche fördern die Genesung , in: Dtsch Arztebl 2021; 118 (45): A 2112–4 September 2021: Selter [...] DOI 10.1055/a-1205-0672 https://eref.thieme.de/ejournals/1439-4421_2020_11?context=cover#/10.1055-a-1205-0672 Print Short version: Gesundheitswesen 2020; 82 (11): 852-853. DOI 10.1055/a-1205-0672 Januar [...] Klinische Ethik. März 2022: Erdmann A, Spoden C, Hirschberg I, Neitzke G (2022). Talking about the end of life: communication patterns in amyotrophic lateral sclerosis – a scoping review. Palliative Care and

64(17): 6058-64 Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH: German CML Study Group [...] 18(1): 113-9 Kreft A, Wiese B, Weiss M, Choritz H, Buhr T, Büsche G, Georgii A: Analysis of Risk Factors of the Evolution of Myelofibrosis in Pre-Fibrotic Chronic Idiopathic Myelofibrosis: A retrospective study [...] Veröffentlichungen 2004 Attaran M, Schneider A, Grote C, Zwiens C, Flemming P, Gratz KF, Jochheim A, Bahr MJ, Manns MP, Ott M: Regional and transient ischemia/reperfusion injury in the liver improves

on all renal transplant biopsies being taken within the IFB-Tx program following a uniquely developed protocol including a complete actual Banff classification (executive nephropathologist since 04/2014) [...] Protocol: QRK306: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain [...] of urine samples. A multicentre diagnostic phase 3 trial Clinical Protocol: 3xBIOS² study: Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN) CCFZ533X2201: A 12-months randomized